Jason Christiansen
About Jason Christiansen
Jason Christiansen is the Chief Technology Officer at Epic Sciences, where he focuses on advancing healthcare through technology. He has over 20 years of experience in research and development, particularly in biomarker application and product development in clinical settings.
Work at Epic Sciences
Jason Christiansen serves as the Chief Technology Officer at Epic Sciences, a role he has held since 2021. In this position, he focuses on advancing the company's technological capabilities and overseeing the development of innovative solutions in the field of precision medicine. His leadership contributes to the mission of Epic Sciences, which emphasizes clarity in diagnostics and treatment options.
Previous Experience at Boundless Bio
Prior to his current role, Jason Christiansen was the Chief Technology Officer at Boundless Bio from 2019 to 2021. During his tenure, he played a key role in guiding the company through its technological advancements and product development processes. His experience in this position further solidified his expertise in bringing early-stage technologies to market.
Education and Expertise
Jason Christiansen earned his PhD in Biophysics from the University of California, Davis, where he studied from 1991 to 1995. His educational background provides a strong foundation for his extensive expertise in biomarker applications in clinical trials, as well as scientific and product development in various diagnostic fields.
Background in Research and Development
With over 20 years dedicated to research and development, Jason Christiansen has significant experience in advancing healthcare and personalized medicine. His background includes roles at Virginia Tech as a Postdoc from 1996 to 2000 and as Senior Director of Assay Development at Genoptix Medical Laboratory from 2011 to 2014. His work encompasses immunoassays, tissue-based testing, and next-generation sequencing.
Achievements in Healthcare Innovation
Jason Christiansen was instrumental in the launch of DefineMBC, a novel liquid biopsy test designed to enhance care for patients with metastatic breast cancer. His contributions to this project highlight his commitment to improving patient outcomes through innovative diagnostic solutions. Additionally, he has successfully implemented platforms and tests in regulated environments, demonstrating his capability in navigating complex development and regulatory pathways.